[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
It is very difficult to reach therapeutic goals of lipids concentrations n patients with very high and high risk development of coronary heart disease during statin monotherapy. Treatment with high doses of statins is associated with significantly increase of serious adverse events, especially rhabdomiolysis. Therefore are taken much more often trials of the combined hypolipemic therapy. In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe.
Broncel
Marlena
M
Department of Internal Diseases with Clinical Pharmacology and Therapy Monitoring Unit, Medical University of Łódź, Poland. ttm@ttm.org.pl
Balcerak
Magdalena
M
Chojnowska-Jezierska
Julita
J
D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000188:drug therapy / Q000517:prevention & control*; D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D002995:Clofibric Acid / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000517:prevention & control; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use; D012307:Risk Factors; D019821:Simvastatin / Q000009:adverse effects / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D001384:Azetidines; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D009525:Niacin; D002995:Clofibric Acid; D019821:Simvastatin; D000069438:Ezetimibe